Concepts (185)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Scleroderma, Systemic | 19 | 2021 | 446 | 2.910 |
Why?
|
| Scleroderma, Diffuse | 9 | 2021 | 25 | 1.580 |
Why?
|
| Lung Diseases, Interstitial | 7 | 2021 | 110 | 1.360 |
Why?
|
| Lung Diseases | 3 | 2013 | 175 | 0.760 |
Why?
|
| Biomarkers | 5 | 2019 | 1593 | 0.590 |
Why?
|
| Aromatase Inhibitors | 1 | 2016 | 17 | 0.550 |
Why?
|
| Proton Pump Inhibitors | 1 | 2016 | 91 | 0.510 |
Why?
|
| Mucin-1 | 2 | 2019 | 35 | 0.510 |
Why?
|
| Bone Density | 1 | 2016 | 159 | 0.510 |
Why?
|
| Perception | 1 | 2016 | 189 | 0.490 |
Why?
|
| Glucocorticoids | 1 | 2016 | 222 | 0.480 |
Why?
|
| Anticonvulsants | 1 | 2016 | 223 | 0.480 |
Why?
|
| Arthrography | 1 | 2013 | 13 | 0.440 |
Why?
|
| Hypertension, Pulmonary | 4 | 2021 | 232 | 0.440 |
Why?
|
| Patient Satisfaction | 1 | 2016 | 378 | 0.440 |
Why?
|
| Registries | 7 | 2021 | 730 | 0.430 |
Why?
|
| Ultrasonography | 1 | 2013 | 453 | 0.380 |
Why?
|
| Skin | 7 | 2019 | 451 | 0.380 |
Why?
|
| Fibroblasts | 6 | 2012 | 902 | 0.380 |
Why?
|
| Mixed Connective Tissue Disease | 1 | 2010 | 9 | 0.370 |
Why?
|
| Scleroderma, Limited | 1 | 2010 | 5 | 0.370 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 1 | 2009 | 15 | 0.340 |
Why?
|
| Respiratory Function Tests | 5 | 2020 | 123 | 0.300 |
Why?
|
| Immunosuppressive Agents | 3 | 2021 | 514 | 0.270 |
Why?
|
| Lung | 5 | 2021 | 849 | 0.260 |
Why?
|
| Patient Reported Outcome Measures | 3 | 2020 | 114 | 0.240 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 2222 | 0.230 |
Why?
|
| Vital Capacity | 5 | 2021 | 43 | 0.230 |
Why?
|
| Humans | 29 | 2021 | 68549 | 0.230 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 2324 | 0.220 |
Why?
|
| Smad1 Protein | 2 | 2012 | 10 | 0.210 |
Why?
|
| Middle Aged | 14 | 2021 | 21119 | 0.200 |
Why?
|
| Acro-Osteolysis | 1 | 2020 | 1 | 0.190 |
Why?
|
| Abatacept | 1 | 2019 | 17 | 0.180 |
Why?
|
| Chemokines, CC | 1 | 2019 | 18 | 0.180 |
Why?
|
| Connective Tissue Growth Factor | 5 | 2012 | 76 | 0.170 |
Why?
|
| Adaptive Immunity | 1 | 2019 | 37 | 0.170 |
Why?
|
| Adult | 11 | 2021 | 21379 | 0.170 |
Why?
|
| Immunity, Innate | 1 | 2019 | 156 | 0.160 |
Why?
|
| Female | 16 | 2021 | 38021 | 0.160 |
Why?
|
| Male | 15 | 2021 | 37283 | 0.160 |
Why?
|
| Severity of Illness Index | 5 | 2021 | 1851 | 0.150 |
Why?
|
| Joints | 1 | 2017 | 30 | 0.150 |
Why?
|
| Hepatocyte Growth Factor | 2 | 2007 | 63 | 0.140 |
Why?
|
| Aged | 8 | 2021 | 14842 | 0.140 |
Why?
|
| Mycophenolic Acid | 3 | 2021 | 62 | 0.140 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2016 | 101 | 0.140 |
Why?
|
| Up-Regulation | 4 | 2012 | 682 | 0.140 |
Why?
|
| Activin Receptors, Type II | 2 | 2012 | 3 | 0.130 |
Why?
|
| Young Adult | 5 | 2019 | 5710 | 0.130 |
Why?
|
| Metabolomics | 1 | 2015 | 28 | 0.130 |
Why?
|
| Vitamins | 1 | 2016 | 134 | 0.130 |
Why?
|
| Osteoporosis | 1 | 2016 | 88 | 0.130 |
Why?
|
| Transforming Growth Factor beta | 3 | 2012 | 384 | 0.120 |
Why?
|
| Signal Transduction | 4 | 2012 | 2689 | 0.120 |
Why?
|
| Prospective Studies | 5 | 2021 | 3703 | 0.120 |
Why?
|
| Oral Hygiene | 1 | 2013 | 33 | 0.110 |
Why?
|
| Dietary Supplements | 1 | 2016 | 331 | 0.110 |
Why?
|
| Longitudinal Studies | 3 | 2021 | 1054 | 0.110 |
Why?
|
| Hospitalization | 1 | 2018 | 977 | 0.110 |
Why?
|
| Matrix Metalloproteinase 1 | 2 | 2010 | 74 | 0.110 |
Why?
|
| Caveolin 1 | 1 | 2012 | 59 | 0.100 |
Why?
|
| Calcium | 1 | 2016 | 929 | 0.100 |
Why?
|
| Vitamin D | 1 | 2016 | 516 | 0.100 |
Why?
|
| Prognosis | 2 | 2021 | 2093 | 0.100 |
Why?
|
| Sensitivity and Specificity | 2 | 2020 | 1753 | 0.100 |
Why?
|
| Antigens, CD | 1 | 2011 | 230 | 0.090 |
Why?
|
| Immediate-Early Proteins | 2 | 2007 | 63 | 0.090 |
Why?
|
| Receptors, Cell Surface | 1 | 2011 | 248 | 0.090 |
Why?
|
| Collagen Type I | 2 | 2010 | 175 | 0.090 |
Why?
|
| Heart Diseases | 1 | 2013 | 276 | 0.090 |
Why?
|
| Primary Health Care | 1 | 2016 | 702 | 0.090 |
Why?
|
| Cyclophosphamide | 2 | 2021 | 129 | 0.090 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2007 | 146 | 0.090 |
Why?
|
| Sequence Analysis, RNA | 2 | 2019 | 34 | 0.090 |
Why?
|
| Risk Factors | 2 | 2018 | 5720 | 0.090 |
Why?
|
| Fibrosis | 2 | 2011 | 371 | 0.090 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2010 | 108 | 0.090 |
Why?
|
| Vascular Diseases | 1 | 2010 | 94 | 0.090 |
Why?
|
| Aged, 80 and over | 2 | 2016 | 4843 | 0.080 |
Why?
|
| Proto-Oncogene Protein c-fli-1 | 1 | 2010 | 106 | 0.080 |
Why?
|
| South Carolina | 1 | 2016 | 2752 | 0.080 |
Why?
|
| Myocardium | 1 | 2015 | 1204 | 0.080 |
Why?
|
| Area Under Curve | 1 | 2009 | 238 | 0.080 |
Why?
|
| Sphingosine | 1 | 2010 | 315 | 0.080 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2010 | 239 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2010 | 331 | 0.080 |
Why?
|
| Surveys and Questionnaires | 1 | 2016 | 2798 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 929 | 0.070 |
Why?
|
| United States | 4 | 2021 | 7338 | 0.070 |
Why?
|
| Disease Progression | 2 | 2019 | 1037 | 0.060 |
Why?
|
| Phosphorylation | 3 | 2012 | 1200 | 0.060 |
Why?
|
| Gene Expression | 2 | 2019 | 770 | 0.050 |
Why?
|
| Chemokine CCL19 | 1 | 2021 | 1 | 0.050 |
Why?
|
| Chemokine CCL8 | 1 | 2021 | 2 | 0.050 |
Why?
|
| Chemokine CXCL9 | 1 | 2021 | 8 | 0.050 |
Why?
|
| beta 2-Microglobulin | 1 | 2021 | 15 | 0.050 |
Why?
|
| Cells, Cultured | 3 | 2012 | 2673 | 0.050 |
Why?
|
| Chemokine CXCL10 | 1 | 2021 | 21 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2021 | 39 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2021 | 27 | 0.050 |
Why?
|
| Patient Care | 1 | 2021 | 61 | 0.050 |
Why?
|
| Methotrexate | 1 | 2021 | 91 | 0.050 |
Why?
|
| Transfection | 2 | 2012 | 782 | 0.050 |
Why?
|
| Hand | 1 | 2020 | 90 | 0.040 |
Why?
|
| Visual Analog Scale | 1 | 2019 | 8 | 0.040 |
Why?
|
| Raynaud Disease | 1 | 2019 | 24 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 68 | 0.040 |
Why?
|
| RNA, Small Interfering | 2 | 2012 | 434 | 0.040 |
Why?
|
| Down-Regulation | 2 | 2012 | 447 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2012 | 1174 | 0.040 |
Why?
|
| Arterial Pressure | 1 | 2018 | 46 | 0.040 |
Why?
|
| Transcriptome | 1 | 2019 | 164 | 0.040 |
Why?
|
| Phenotype | 2 | 2011 | 946 | 0.040 |
Why?
|
| Biopsy | 1 | 2019 | 539 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2019 | 737 | 0.040 |
Why?
|
| Self Report | 1 | 2019 | 370 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 498 | 0.040 |
Why?
|
| Adolescent | 2 | 2019 | 8904 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 1046 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2019 | 621 | 0.040 |
Why?
|
| Cell Culture Techniques | 2 | 2007 | 189 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 791 | 0.030 |
Why?
|
| Physical Examination | 1 | 2017 | 152 | 0.030 |
Why?
|
| Survival Rate | 1 | 2018 | 1055 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2019 | 1738 | 0.030 |
Why?
|
| Echocardiography | 1 | 2018 | 515 | 0.030 |
Why?
|
| Autopsy | 1 | 2015 | 56 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2021 | 2356 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2017 | 298 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2015 | 164 | 0.030 |
Why?
|
| Sex Factors | 1 | 2018 | 1265 | 0.030 |
Why?
|
| Dyspnea | 1 | 2015 | 87 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2016 | 483 | 0.030 |
Why?
|
| Mouthwashes | 1 | 2013 | 9 | 0.030 |
Why?
|
| Toothbrushing | 1 | 2013 | 21 | 0.030 |
Why?
|
| Dental Devices, Home Care | 1 | 2013 | 17 | 0.030 |
Why?
|
| Xerostomia | 1 | 2013 | 24 | 0.030 |
Why?
|
| Hemodynamics | 1 | 2016 | 705 | 0.030 |
Why?
|
| Dental Care | 1 | 2013 | 34 | 0.030 |
Why?
|
| Mouth | 1 | 2013 | 64 | 0.030 |
Why?
|
| Motor Skills | 1 | 2013 | 88 | 0.030 |
Why?
|
| Oral Health | 1 | 2013 | 49 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2013 | 122 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 132 | 0.030 |
Why?
|
| Endoglin | 1 | 2011 | 3 | 0.030 |
Why?
|
| Smad3 Protein | 1 | 2011 | 33 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 3256 | 0.030 |
Why?
|
| Smad2 Protein | 1 | 2011 | 42 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 2077 | 0.020 |
Why?
|
| RNA Interference | 1 | 2011 | 266 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2011 | 326 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2013 | 424 | 0.020 |
Why?
|
| Endothelin-1 | 1 | 2011 | 122 | 0.020 |
Why?
|
| Attitude to Health | 1 | 2013 | 403 | 0.020 |
Why?
|
| Butadienes | 1 | 2010 | 26 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2012 | 954 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2010 | 71 | 0.020 |
Why?
|
| Microcirculation | 1 | 2010 | 77 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2010 | 81 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2011 | 791 | 0.020 |
Why?
|
| Nitriles | 1 | 2010 | 68 | 0.020 |
Why?
|
| Permeability | 1 | 2010 | 131 | 0.020 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 1 | 2010 | 65 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2010 | 147 | 0.020 |
Why?
|
| Alleles | 1 | 2010 | 386 | 0.020 |
Why?
|
| Actins | 1 | 2010 | 249 | 0.020 |
Why?
|
| Collagen | 1 | 2011 | 636 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2020 | 7268 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2019 | 7028 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2011 | 1663 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2007 | 82 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2010 | 331 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2013 | 2265 | 0.020 |
Why?
|
| Depression | 1 | 2013 | 942 | 0.020 |
Why?
|
| Mutation | 1 | 2011 | 1213 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2007 | 247 | 0.020 |
Why?
|
| Reference Values | 1 | 2007 | 579 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 507 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2007 | 320 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2010 | 1692 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2007 | 432 | 0.020 |
Why?
|
| Cytokines | 1 | 2007 | 866 | 0.010 |
Why?
|
| Mice | 1 | 2010 | 8474 | 0.010 |
Why?
|
| Animals | 1 | 2010 | 20880 | 0.010 |
Why?
|